The large randomized pediatric entecavir study for Hepatitis B virus (HBV) is now in print: MM Jonas et al. Hepatology 2016; 63: 377-87. Full link to this study on previous blog: Pediatric Entecavir Data This study has led to FDA approval for use of entecavir in children as young as 2 years. One interesting aspect of the study was the 2.6% drug resistance rate in the second year of the study. This further validates current recommendations to treat children with “immune active” phases (e.g. abnormal transaminases and abnormal histology).
Briefly noted:
H Roberts et al. Hepatology 2016; 63: 388-97. This study provides prevalence data for chronic HBV, 1988-2012. During 2011-12, there were approximately 850,000 Americans with chronic HBV infections. Migration of persons from HBV endemic countries has “largely contributed to prevalence rates remaining constant since 1999.”
JM Wilder et al. Hepatology 2016; 63: 437-44. This study showed that ledipasvir/sofosbuvir was similarly effective in black and non-black patients, with SVR12 rates of 95% and 97% respectively. This is important because older interferon-based treatments were much less effective in black patients.
TB Dick et al. Hepatology 2016; 63: 634-43. This review provides in-depth guidance regarding drug-drug interactions relevant to the new direct-acting antiviral agents used to treat Hepatitis C viral infection.
NY City Data for HIV, HBV, HCV
gutsandgrowth 